Lysosomal storage disorders: Molecular basis and laboratory testing
Tóm tắt
Lysosomal storage disorders (LSDs) are a large group of more than 50 different inherited metabolic diseases which, in the great majority of cases, result from the defective function of specific lysosomal enzymes and, in cases, of non-enzymatic lysosomal proteins or non-lysosomal proteins involved in lysosomal biogenesis. The progressive lysosomal accumulation of undegraded metabolites results in generalised cell and tissue dysfunction, and, therefore, multi-systemic pathology. Storage may begin during early embryonic development, and the clinical presentation for LSDs can vary from an early and severe phenotype to late-onset mild disease. The diagnosis of most LSDs--after accurate clinical/paraclinical evaluation, including the analysis of some urinary metabolites--is based mainly on the detection of a specific enzymatic deficiency. In these cases, molecular genetic testing (MGT) can refine the enzymatic diagnosis. Once the genotype of an individual LSD patient has been ascertained, genetic counselling should include prediction of the possible phenotype and the identification of carriers in the family at risk. MGT is essential for the identification of genetic disorders resulting from non-enzymatic lysosomal protein defects and is complementary to biochemical genetic testing (BGT) in complex situations, such as in cases of enzymatic pseudodeficiencies. Prenatal diagnosis is performed on the most appropriate samples, which include fresh or cultured chorionic villus sampling or cultured amniotic fluid. The choice of the test--enzymatic and/or molecular--is based on the characteristics of the defect to be investigated. For prenatal MGT, the genotype of the family index case must be known. The availability of both tests, enzymatic and molecular, enormously increases the reliability of the entire prenatal diagnostic procedure. To conclude, BGT and MGT are mostly complementary for post- and prenatal diagnosis of LSDs. Whenever genotype/phenotype correlations are available, they can be helpful in predicting prognosis and in making decisions about therapy.
Tài liệu tham khảo
Tay W: Symmetrical changes in the region of the yellow spot in each eye of an infant. Trans Opthalmol Soc. 1881, 1: 55-57.
Sachs B: On arrested cerebral development with special reference to cortical pathology. J Nerv Ment Dis. 1887, 14: 541-554.
Gaucher PCE: De l'epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie. Academic thesis, Paris, France. 1882
Capper A, Epstein H, Schless RA: Gaucher's disease. Report of a case with presentation of a table differentiating the lipoid disturbances. Am J Med Sci. 1934, 188: 84-10.1097/00000441-193407000-00012.
Hers HG: Alpha-glucosidase activity in generalized glycogen storage disease (Pompe's disease). Biochem J. 1963, 86: 11-
Ballabio A, Gieselmann V: Lysosomal disorders: From storage to cellular damage. Biochim Biophys Acta. 2009, 1793: 684-696. 10.1016/j.bbamcr.2008.12.001.
Wraith JE: Lysosomal disorders. Semin Neonatol. 2002, 7: 75-83. 10.1053/siny.2001.0088.
Futerman AH, van Meer G: The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol. 2004, 5: 554-565. 10.1038/nrm1423.
Vellodi A: Lysosomal storage disorders. Br J Haematol. 2005, 128: 413-431. 10.1111/j.1365-2141.2004.05293.x.
Vitner EB, Platt FM, Futerman AH: Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem. 2010, 285: 20423-20427. 10.1074/jbc.R110.134452.
Boot RG, Renkema H, Verhoek M, Strijland A, et al: The human chitotriosidase gene. J Biol Chem. 1998, 273: 25680-25685. 10.1074/jbc.273.40.25680.
De Duve C, Wattiaux R: Functions of lysosomes. Annu Rev Physiol. 1966, 28: 435-492. 10.1146/annurev.ph.28.030166.002251.
Maxfield FR, McGraw TE: Endocytic recycling. Nat Rev Mol Cell Biol. 2004, 5: 121-132. 10.1038/nrm1315.
Hickman S, Neufeld EF: A hypothesis for I-cell disease: Defective hydrolases that do not enter lysosomes. Biochem Biophys Res Commun. 1972, 49: 992-999. 10.1016/0006-291X(72)90310-5.
Reitman ML, Kornfeld S: UDP-N-acetylglucosamine: glycoprotein N-acetylglucosamine-1-phosphotransferase. Proposed enzyme for the phosphorylation of the high mannose oligosaccharide units of lysosomal enzymes. J Biol Chem. 1981, 256: 4275-4281.
Waheed A, Hasilik A, von Figura K: Processing of the phosphorylated recognition marker in lysosomal enzymes. Characterization and partial purification of a microsomal alpha-N-acetylglucosaminyl phosphodiesterase. J Biol Chem. 1981, 256: 5717-5721.
Reczek D, Schwake M, Schröder J, Hughes H, et al: LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell. 2007, 131: 770-783. 10.1016/j.cell.2007.10.018.
Beutler E, Grabowski G: Gaucher disease. The Metabolic and Molecular Bases of Inherited Disease. Edited by: Scriver CR, et al. 2001, McGraw-Hill, New York, NY, 3635-3668. 8
Vallance H, Ford J: Carrier testing for autosomal-recessive disorders. Crit Rev Clin Lab Sci. 2003, 40: 473-497. 10.1080/10408360390247832.
Arvio M, Autio S, Louhiala P: Early clinical symptoms and incidence of aspartylglucosaminuria in Finland. Acta Paediatr. 1993, 82: 587-589. 10.1111/j.1651-2227.1993.tb12761.x.
Santavuori P: Neuronal ceroid-lipofuscinoses in childhood. Brain Dev. 1988, 10: 80-83. 10.1016/S0387-7604(88)80075-5.
Michelakakis H, Dimitriou E, Tsagaraki S, Giouroukos S, et al: Lysosomal storage diseases in Greece. Genet Couns. 1995, 6: 43-47.
Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, et al: The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999, 105: 151-156.
Meikle PJ, Hopwood JJ, Clague AE, Carey WF: Prevalence of lysosomal storage disorders. JAMA. 1999, 281: 249-254. 10.1001/jama.281.3.249.
Pinto R, Caseiro C, Lemos M, Lopes L, et al: Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet. 2004, 12: 87-92. 10.1038/sj.ejhg.5201044.
Poupětová H, Ledvinová J, Berná L, Dvoráková L, et al: The birth prevalence of lysosomal storage disorders in the Czech Republic: Comparison with data in different populations. J Inherit Metab Dis. 2010, 33: 387-396. 10.1007/s10545-010-9093-7.
Jalanko A, Braulke T: Neuronal ceroid lipofuscinoses. Biochim Biophys Acta. 2009, 1793: 697-709. 10.1016/j.bbamcr.2008.11.004.
Cosma MP, Pepe S, Annunziata I, Newbold RF, et al: The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell. 2003, 113: 445-456. 10.1016/S0092-8674(03)00348-9.
Dierks T, Schmidt B, Borissenko LV, Peng J, et al: Multiple sulfatase deficiency is caused by mutations in the gene encoding the human Cα-formylglycine generating enzyme. Cell. 2003, 113: 435-444. 10.1016/S0092-8674(03)00347-7.
D'Azzo A, Andria G, Strisciuglio P, Galjaard H: Galactosialidosis. The Metabolic and Molecular Bases of Inherited Diseases. Edited by: Scriver CR, et al. 2001, McGraw-Hill, New York, NY, 3811-3826. 8
Conzelmann E, Sandhoff K: Partial enzyme deficiencies: Residual activities and the development of neurological disorders. Dev Neurosci. 1983, 6: 58-71. 10.1159/000112332.
O'Brien JS, Kretz KA, Dewji N, Wenger DA, et al: Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus. Science. 1988, 41: 1098-1101.
Spiegel R, Bach G, Sury V, Mengistu G, et al: A mutation in the saposin A coding region of the prosaposin gene in an infant presenting as Krabbe disease: First report of saposin A deficiency in humans. Mol Genet Metab. 2005, 84: 160-166. 10.1016/j.ymgme.2004.10.004.
Wenger DA, De Gala G, Williams C, Taylor HA, et al: Clinical, pathological, and biochemical studies on an infantile case of sulfatide/GM1 activator protein deficiency. Am J Med Genet. 1989, 33: 255-265. 10.1002/ajmg.1320330223.
Christomanou H, Chabas A, Pampols T, Guardiola A: Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder. Wien Klin Wochenschr. 1989, 67: 999-1003.
Bradova V, Smid F, Ulrich-Bott B, Roggendorf W, et al: Prosaposin deficiency: Further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease. Hum Genet. 1993, 92: 143-152. 10.1007/BF00219682.
Kornfeld S, Sly WS: I-cell disease and pseudo-Hurler polydystrophy: Disorders of lysosomal enzyme phosphorylation and localization. The Metabolic and Molecular Bases of Inherited Diseases. Edited by: Scriver CR, et al. 2001, McGraw-Hill, New York, NY, 3469-3505. 8
Gieselmann V, Polten A, Kreysing J, von Figura K: Arylsulfatase A pseudodeficiency: Loss of a polyadenylation signal and N-glycosylation site. Proc Natl Acad Sci USA. 1989, 86: 9436-9440. 10.1073/pnas.86.23.9436.
Cao Z, Petroulakis E, Salo T, Triggs-Raine B: Benign HEXA mutations, C739T(R247W) and C745T(R249W), cause betahexosaminidase A pseudodeficiency by reducing the alpha-subunit protein levels. J Biol Chem. 1997, 272: 14975-14982. 10.1074/jbc.272.23.14975.
Aronovich EL, Pan D, Whitley CB: Molecular genetic defect underlying alpha-L-iduronidase pseudodeficiency. Am J Hum Genet. 1996, 58: 75-85.
Nishimoto J, Inui K, Okada S, Ishigami W, et al: A family with pseudodeficiency of acid alpha-glucosidase. Clin Genet. 1988, 33: 254-261.
Froissart R, Guffon N, Vanier MT, Desnick RJ, et al: Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab. 2003, 80: 307-314. 10.1016/S1096-7192(03)00136-7.
Hoffmann B, Georg Koch H, Schweitzer-Krantz S, Wendel U, et al: Deficient alpha-galactosidase A activity in plasma but no Fabry disease -- A pitfall in diagnosis. Clin Chem Lab Med. 2005, 43: 1276-1277.
Gort L, Santamaria R, Grinberg D, Vilageliu L, et al: Identification of a novel pseudodeficiency allele in the GLB1 gene in a carrier of GM1 gangliosidosis. Clin Genet. 2007, 72: 109-111. 10.1111/j.1399-0004.2007.00843.x.
Wauters JG, Stuer KL, Elsen AV, Willems PJ: α-L-fucosidase in human fibroblasts. I. The enzyme activity polymorphism. Biochem Genet. 1992, 30: 131-141. 10.1007/BF02399704.
Chabas A, Giros ML, Guardiola A: Low β-glucuronidase activity in a healthy member of a family with mucopolysaccharidosis VII. J Inherit Metab Dis. 1991, 14: 908-914. 10.1007/BF01800472.
Vervoort R, Islam MR, Sly W, Chabas A, et al: A pseudo-deficiency allele (D152N) of the human beta-glucuronidase gene. Am J Hum Genet. 1995, 57: 798-804.
Gieselmann V: An assay for the rapid detection of the arylsulfatase A pseudodeficiency allele facilitates diagnosis and genetic counseling for metachromatic leukodystrophy. Hum Genet. 1991, 86: 251-255.
Chabás A, Castellvi S, Bayés M, Balcells S, et al: Frequency of the arylsulphatase A pseudodeficiency allele in the Spanish population. Clin Genet. 1993, 44: 320-323.
Regis S, Filocamo M, Stroppiano M, Corsolini F, et al: Molecular analysis of the arylsulfatase A gene in late infantile metachromatic leukodystrophy patients and healthy subjects from Italy. J Med Genet. 1996, 33: 251-252. 10.1136/jmg.33.3.251.
Shen N, Li ZG, Waye JS, Francis G, et al: Complications in the genotypic molecular diagnosis of pseudoarylsulfatase A deficiency. Am J Med Genet. 1993, 45: 631-637. 10.1002/ajmg.1320450523.
Sandhoff K, Kolter T, Harzer K: Sphingolipid activator proteins. The Metabolic and Molecular Bases of Inherited Diseases. Edited by: Scriver CR, et al. 2001, McGraw-Hill, New York, NY, 3371-3388. 8
Grossi S, Regis S, Rosano C, Corsolini F, et al: Molecular analysis of ARSA and PSAP genes in twenty-one Italian patients with metachromatic leukodystrophy: Identification and functional characterization of 11 novel ARSA alleles. Hum Mutat. 2008, 29: E220-E230. 10.1002/humu.20851.
Thomas GH: "Pseudodeficiencies" of lysosomal hydrolases. Am J Hum Genet. 1994, 54: 934-940.
Tylki-Szymańska A, Czartoryska B, Vanier MT, Poorthuis BJ, et al: Non-neuronopathic Gaucher disease due to saposin C deficiency. Clin Genet. 2007, 72: 538-542. 10.1111/j.1399-0004.2007.00899.x.
Parenti G: Treating lysosomal storage diseases with pharmacological chaperones: From concept to clinics. EMBO Mol Med. 2009, 1: 268-279. 10.1002/emmm.200900036.
Schiffmann R: Therapeutic approaches for neuronopathic lysosomal storage disorders. J Inherit Metab Dis. 2010, 33: 373-379. 10.1007/s10545-010-9047-0.
Lualdi S, Tappino B, Di Duca M, Dardis A, et al: Enigmatic in vivo iduronate-2-sulfatase (IDS) mutant transcript correction to wild-type in Hunter syndrome. Hum Mutat. 2010, 31: 1261-1285. 10.1002/humu.21356.
Ishii S, Nakao S, Minamikawa-Tachino R, Desnick RJ, et al: Alternative splicing in the alpha-galactosidase A gene: Increased exon inclusion results in the Fabry cardiac phenotype. 2002, 70: 994-1002.
Filoni C, Caciotti A, Carraresi L, Donati MA, et al: Unbalanced GLA mRNAs ratio quantified by real-time PCR in Fabry patients' fibroblasts results in Fabry disease. Eur J Hum Genet. 2008, 16: 1311-1317. 10.1038/ejhg.2008.109.
Filocamo M, Bonuccelli G, Mazzotti R, Corsolini F, et al: Somatic mosaicism in a patient with Gaucher disease type 2: Implication for genetic counselling and therapeutic decision-making. Blood Cell Mol Dis. 2000, 26: 611-612. 10.1006/bcmd.2000.0341.
Caciotti A, Bardelli T, Cunningham J, D'Azzo A, et al: Modulating action of the new polymorphism L436F detected in the GLB1 gene of a type-II GM1 gangliosidosis patient. Hum Genet. 2003, 113: 44-50.
Lualdi S, Regis S, Di Rocco M, Corsolini F, et al: Characterization of iduronate-2-sulfatase gene-pseudogene recombinations in eight patients with mucopolysaccharidosis type II revealed by a rapid PCR-based method. Hum Mutat. 2005, 25: 491-497. 10.1002/humu.20165.
Tayebi N, Stubblefield BK, Park JK, Orvisky E, et al: Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: Implications for complexity in Gaucher disease. Am J Hum Genet. 2003, 72: 519-534. 10.1086/367850.
Filocamo M, Regis S, Mazzotti R, Parenti G, et al: A simple non-isotopic method to show pitfalls during mutation analysis of the glucocerebrosidase gene. J Med Genet. 2001, 38: E34-10.1136/jmg.38.10.e34.
Zanetti A, Ferraresi E, Picci L, Filocamo M, et al: Segregation analysis in a family at risk for the Maroteaux-Lamy syndrome conclusively reveals c.1151G > A (p.S384N) as to be a polymorphism. Eur J Hum Genet. 2009, 17: 1160-1164. 10.1038/ejhg.2009.19.
Lehotay DC, Hall P, Lepage J, Eichhorst JC, et al: LC-MS/MS progress in newborn screening. Clin Biochem. 2010, 44: 21-31.
Chamoles NA, Blanco M, Gaggioli D: Fabry disease: Enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta. 2001, 308: 195-196. 10.1016/S0009-8981(01)00478-8.
Chamoles NA, Blanco M, Gaggioli D, Casentini C: Gaucher and Niemann-Pick diseases -- Enzymatic diagnosis in dried blood spots on filter paper: Retrospective diagnoses in newborn-screening cards. Clin Chim Acta. 2002, 317: 191-197. 10.1016/S0009-8981(01)00798-7.
Chamoles NA, Blanco MB, Gaggioli D, Casentini C: Hurler-like phenotype: Enzymatic diagnosis in dried blood spots on filter paper. Clin Chem. 2001, 47: 2098-2102.
Gelb MH, Turecek F, Scott CR, Chamoles NA: Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis. 2006, 29: 397-404. 10.1007/s10545-006-0265-4.
Li Y, Scott CR, Chamoles NA, Ghavami A, et al: Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem. 2004, 50: 1785-1796. 10.1373/clinchem.2004.035907.
La Marca G, Casetta B, Malvagia S, Guerrini R, et al: New strategy for the screening of lysosomal storage disorders: The use of theonline trapping-and-cleanup liquid chromatography/mass spectrometry. Anal Chem. 2009, 1: 6113-6121.
Fletcher JM: Screening for lysosomal storage disorders -- A clinical perspective. J Inherit Metab Dis. 2006, 29: 405-408. 10.1007/s10545-006-0246-7.
Zhang XK, Elbin CS, Chuang WL, Cooper SK, et al: Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem. 2008, 54: 1725-1728. 10.1373/clinchem.2008.104711.
De Jesus VR, Zhang XK, Keutzer J, Bodamer OA, et al: Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage disorders. Clin Chem. 2009, 55: 158-164.
Dajnoki A, Mühl A, Fekete G, Keutzer J, et al: Newborn screening for Pompe disease by measuring acid alpha-glucosidase activity using tandem mass spectrometry. Clin Chem. 2008, 54: 1624-1629. 10.1373/clinchem.2008.107722.
Kooper AJ, Janssens PM, de Groot AN, Liebrand-van Sambeek ML, et al: Lysosomal storage diseases in non-immune hydrops fetalis pregnancies. Clin Chim Acta. 2006, 371: 176-182. 10.1016/j.cca.2006.03.007.
Malvagia S, Morrone A, Caciotti A, Bardelli T, et al: New mutations in the PPBG gene lead to loss of PPCA protein which affects the level of the beta-galactosidase/neuraminidase complex and the EBP-receptor. Mol Genet Metab. 2004, 82: 48-55. 10.1016/j.ymgme.2004.02.007.
Froissart R, Cheillan D, Bouvier R, Tourret S, et al: Clinical, morphological, and molecular aspects of sialic acid storage disease manifesting in utero. J Med Genet. 2005, 42: 829-836. 10.1136/jmg.2004.029744.